[13/01/2019] – Today the Scottish Medicines Consortium (SMC) accepts the use of new migraine drug AJOVY®▼ (fremanezumab) within NHS Scotland. The treatment, for both chronic and episodic migraine, is not yet available to NHS patients in other parts of the UK.

Teva UK Limited’s migraine drug AJOVY® has today been accepted by the SMC for use within NHS Scotland. The treatment could help some of the estimated 740,000 Scottish migraine patients; those with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.1 Migraine affects three-times as many women as men, with research suggesting 190,000 migraine attacks occur every day in the UK.2

AJOVY® belongs to a class of treatments called anti-CGRP (calcitonin gene-related peptide) monoclonal antibodies, which have been specifically designed to target the underlying causes of migraine. AJOVY® is the first anti-CGRP therapy to be accepted by the SMC for both chronic and episodic migraine. It is also the only licensed anti-CGRP therapy to offer both quarterly and monthly dosing options.1 

Migraine usually involves a combination of symptoms that can include headache, nausea, vomiting, and sensitivity to light, noise or smell.3 It is the third most common condition in the world, and has a significant financial burden on the UK economy, estimated at £3.42 billion per year.2 It is the seventh most common cause of disease burden in Scotland, and across all age groups women experienced a greater proportion of the migraine burden than men.4

“I am delighted that SMC have approved AJOVY® for use in Scotland,” said Dr David Watson, GP with a Special Interest in Headache at the Department of Neurology, Aberdeen Royal Infirmary. “The clinical trials show that it can reduce migraine frequency and severity and make a significant impact in patients with migraine disability. As a practising clinician it is very helpful to have more options to treat patients with migraine.”

“Teva is very pleased with the SMC decision, as we seek to expand the availability of AJOVY® across the UK in an effort to ensure that patients living with migraine have access to this treatment option,” said Kim Innes, General Manager of Teva UK and Ireland. “We’re committed to improving the lives of migraine patients. I believe that the introduction of AJOVY® in Scotland, having been accepted by the SMC for prevention of both chronic and episodic migraine, and with its flexible dosing options, will bring new opportunities and enable better days for those struggling to control this disabling condition.”

 

References

1. AJOVY® SmPC. Teva UK Limited

2. Migraine: Facts & Figures. The Migraine Trust - https://www.migrainetrust.org/about-migraine/migraine-what-is-it/facts-figures/. Last accessed: January 2020

3. Migraine – A Comprehensive Guide. NHS. https://www.thewaltoncentre.nhs.uk/uploadedfiles/leaflets/Migraine%20-%20A%20Comprehensive%20Guide.pdf. Last accessed: January 2020

4. Scottish Public Health Observatory. The Scottish Burden of Disease Study, 2016: Migraine technical overview. Available at: https://www.scotpho.org.uk/media/1784/sbod2016-migraine2.pdf. Last accessed: January 2020

 

UK/CPE/18/0019(1)j

Date of Preparation: January 2020